FATE Stock Analysis: Buy, Sell, or Hold?
FATE - Fate Therapeutics, Inc.
$2.43
-0.11 (-4.33%)
âŧ
5d:
+4.29%
30d:
-3.19%
90d:
-14.44%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When FATE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: FATE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: FATE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: FATE is currently trading at $2.43, which is considered fair relative to its 30-day fair value range of $2.42 to $2.69.
Technical Outlook: Technically, FATE is in a strong uptrend. Immediate support is located at $2.23, while resistance sits at $2.70. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: FATE scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.74 (+136.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FATE is in a strong uptrend. Immediate support is located at $2.23, while resistance sits at $2.70. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: FATE scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $5.74 (+136.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.42 -
$2.69
Company Quality Score
37/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 136.4% below Wall St target ($5.74)
- WARNING: Composite score 37/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.42 -
$2.69
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.23
Resistance Level
$2.70
Current Trend
Strong Uptrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.51
Wall Street Target
$5.74
(+136.4%)
Revenue Growth (YoY)
9.2%
Share & Embed Analysis
Last updated: August 29, 2026 10:08 PM ET
Data refreshes hourly during market hours. Next update: 11:08 PM
Data refreshes hourly during market hours. Next update: 11:08 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FATE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$370 | 41 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 42 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 38 SELL |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
